Table 1.
Demographic profile and risk factors
| Characteristics | Characteristics | Total, n = 70 (%) |
|---|---|---|
| Age | Median years (IQR) | 44.5 (38–55.5) |
| Gender | Male | 42 (60) |
| Female | 28 (40) | |
| Duration between COVID-19 onset and mucormycosis onset | Median days (IQR) (n = 63) | 20 (13.5–25) |
| COVID-19 status on arrival | Positive at presentation | 53 (75.7) |
| Post-COVID, negative | 17 (24.3) | |
| Comorbid illness | Diabetes | 49 (70) |
| On oral antidiabetic agents | 33 | |
| On insulin | 9 | |
| Recently diagnosed | 5 | |
| Hypertension | 17 (24.3) | |
| Coronary artery diseases | 4 (5.7) | |
| Organ transplant | 2 (2.9) | |
| Chronic kidney diseases | 6 (8.6) | |
| Long term immunosuppressive therapy | Prior steroid use | 3 (4.3) |
| Any other immunosuppressant | 1 (1.4) | |
| Steroid use in the recent COVID-19 | Received systemic steroids | 49 (70) |
| Route of systemic steroids | Intravenous | 27 (38.6) |
| Oral | 22 (31.4) | |
| Type of steroids | Methylprednisolone | 15 (21.4) |
| Dexamethasone | 14 (20) | |
| Prednisolone | 7 (10) | |
| Hydrocortisone | 1 (1.4) | |
| Budesonide | 13 (18.8) | |
| Duration of steroids used | Median days (IQR) (n = 50) | 7.5 (7–10.5) |
| Complication of steroid use | Hyperglycaemia during steroid use which required in-hospital insulin | 33 |
| Inhalational steroid use | Inhalational | 13 (18.8) |
IQR, interquartile range.